Verona Pharma plc Verona Pharma Plc: Pdmr Dealing -- Purchase By Chairman
November 18 2019 - 2:00AM
UK Regulatory
TIDMVRP
LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on respiratory diseases, announces that Dr. David
Ebsworth, Chairman of the Company, has notified the Company that he has
purchased a further 25,000 ordinary shares of 5 pence each in the
Company ("Ordinary Shares") at a total purchase price of GBP11,750, at a
price of 47 pence per Ordinary Share. This purchase brings the total
purchases made by Dr. Ebsworth during 2019 to approximately GBP125,000.
Following the purchase, Dr. Ebsworth will have an interest in the
Company of 395,387 Ordinary Shares, representing 0.38% of the Company's
issued share capital.
Further information is provided below in accordance with the
requirements of the EU Market Abuse Regulation.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely associated
with them
1 Details of the person discharging managerial responsibilities/person
closely associated
--- ----------------------------------------------------------------------
a) Name David Ebsworth
--- ----------------------------------------- ---------------------------
2 Reason for the notification
--- ----------------------------------------------------------------------
Chairman
a) Position/status
--- ----------------------------------------- ---------------------------
b) Initial notification/Amendment Initial notification
--- ----------------------------------------- ---------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- ----------------------------------------------------------------------
a) Name Verona Pharma plc
--- ----------------------------------------- ---------------------------
b) LEI 213800EVI6O6J3TIAL06
--- ----------------------------------------- ---------------------------
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
--- -----------------------------------------------------------------------
Description of the
financial instrument,
a) type of instrument Ordinary Shares of 5 pence each
---
Identification code GB00BYW2KH80
--- --------------------- ------------------------------------------------
Nature of the
b) transaction David Ebsworth purchased 25,000 Ordinary Shares
--- --------------------- ------------------------------------------------
Price(s) and
c) volume(s) Price(s) Volume(s)
--- --------------------- ---------------------- ------------------------
47 pence 25,000
------------------------------------------------ ------------------------
d) Aggregated N/A
information
--- ------------------------------------------------
- Aggregated volume
------------------------
- Price
--------------------------------------------- ------------------------
e) Dates of the 14-Nov-19
transactions
--- --------------------- ------------------------------------------------
f) Place of the London Stock Exchange, AIM
transactions
--- --------------------- ------------------------------------------------
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Victoria Stewart, Director of Communications
N+1 Singer Tel: +44 (0)20 3283 4200
(Nominated Adviser and UK Broker)
Aubrey Powell / George Tzimas (Corporate Finance)
Mia Gardner (Corporate Broking)
(END) Dow Jones Newswires
November 18, 2019 02:00 ET (07:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024